News

The Novel Kit Inhibitor IDRX-42 Shows Promising Activity In 2nd And Later-line Gastrointestinal Stromal Tumors: Results From A Phase 1 Study (StrateGIST 1)

StrateGIST 1: a first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)

Phase 1 Study of IDRX-42 in Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Prior Systemic Therapy: Early Results

Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors

Anti-tumor Effects of the Novel KIT Inhibitor IDRX-42 (formerly M4205) in Gastrointestinal Stromal Tumor (GIST) Xenograft Models